Over 10,000 women enrolled at over 1,000 sites

The largest randomised adjuvant breast cancer treatment trial ever conducted

TAILORx was independently led by ECOG-ACRIN Cancer Research Group with sponsorship from the National Cancer Institute. Participating cancer research groups included the Alliance for Clinical Trials in Oncology, NCIC-Clinical Trials Group, NRG Oncology, and SWOG.


Read the article on NEJM

TAILORX: TRANSFORMING THE TREATMENT OF BREAST CANCER

The TAILORx trial followed over 10,000 women with early breast cancer for an average of 9 years. Over 1,000 trial sites in 6 countries participated.

The Oncotype DX Breast Recurrence Score test is the only genomic test proven to predict a patient's individual benefit of chemotherapy.


Learn more about the test
REFERENCES

  1. Sparano et al. N Engl J Med. 2015.
  2. Sparano et al. N Engl J Med. 2018.

NIH = National Institute of Health

RS = Recurrence Score result

TAILORx = A Clinical Trial Assigning IndividuaLized Options for Treatment (Rx)

The TAILORx trial was conducted independently by the ECOG-ACRIN Cancer Research Group.

Copyright © 2004- Genomic Health, Inc., an Exact Sciences corporation. All Rights Reserved.
In the US and certain other jurisdictions, Genomic Health, Oncotype DX, Oncotype IQ, Recurrence Score, Oncotype DX Breast Recurrence Score, Oncotype DX Colon Recurrence Score, Oncotype DX Genomic Prostate Score, and Oncotype DX AR-V7 Nucleus Detect are registered trademarks, and "Making cancer care smarter" and GPS are pending registered trademarks, of Genomic Health, Inc., an Exact Sciences corporation.
Making cancer care smarter.™